MétaCan
Menu
← Back to cohort

A phase I study of AL101, a pan-NOTCH inhibitor, in patients (pts) with locally advanced or metastatic solid tumors.

2018· article· en· W2890046006 on OpenAlexaff
Anthony B. El-Khoueiry, Jayesh Desai, Swaminathan P. Iyer, Shirish M. Gadgeel, Suresh S. Ramalingam, Leora Horn, Patricia LoRusso, Gaurav Bajaj, Georgia Kollia, Zhenhao Qi, Shashwati Basak, Bruce S. Fischer, Matti Davis, Philippe L. Bédard

Bibliographic record

VenueJournal of Clinical Oncology · 2018
Typearticle
Languageen
FieldMedicine
TopicLung Cancer Treatments and Mutations
Canadian institutionsPrincess Margaret Cancer Centre
Fundersnot available
KeywordsMedicineVomitingNauseaInternal medicineTolerabilityPharmacodynamicsHypokalemiaGastroenterologyPharmacokineticsAdverse effect

Abstract

fetched live from OpenAlex

2515 Background: Notch signaling can be deregulated in human cancer. AL101 (formerly BMS-906024), a gamma secretase inhibitor that potently inhibits all Notch receptors, was evaluated. The primary objective was safety and tolerability of multiple IV doses of AL101 and to establish a RP2D. Methods: Pts with advanced tumors refractory to standard therapies were included. Primary and secondary endpoints included safety, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity. Cohorts were administered escalating doses of AL101 IV weekly (QW) or q 2 weeks (Q2W) using a 3+3 design, with expansion at the MTD in TNBC, NSCLC, and selected other tumors with reported Notch activation. The DLT period was 4 weeks (4 doses QW or 2 doses Q2W). PD markers of Notch activity, including HES1 mRNA, were evaluated in serial whole blood. Results: As of 1Feb2018, preliminary data are available on 94 pts dosed at 0.3 mg to 8.4 mg QW, and 4 mg to 6 mg Q2W. The MTD for QW was 4 mg with 0 DLTs in 7 evaluable pts; DLTs occurred at 8.4 mg QW (Gr 3 infusion reaction, Gr 3 vomiting, Gr 5 liver failure) and 6 mg in de-escalation (Gr 3 vomiting/lipase elevation, Gr 3 diarrhea [n = 3]). The MTD for Q2W was 6 mg, with 1 DLT in 6 evaluable pts (Gr 3 diarrhea). In escalation/expansion at the QW MTD (n = 43), Gr 3 or higher related AEs were: hypophosphatemia (42%), diarrhea (16%), hypokalemia (7%), and anaphylaxis, anemia, AST increase, nausea, pruritus, and vomiting (2% each). There were dose related increases in exposures over 0.3 to 8.4 mg, and the mean plasma half-life following 4 doses QW was 67 - 148 hours, supporting QW dosing. Dose related reduction of HES1 mRNA was seen with > 80% peak inhibition and > 50% inhibition sustained over several days at QW doses of 4 mg and higher. Objective responses were seen in 4 pts (RECIST v1.1): gastroesophageal junction adenocarcinoma (n = 1, 1 cCR ongoing > 1 y), desmoid tumor (n = 3, 2 cPR, ongoing > 1 y, > 3 y), adenoid cystic carcinoma (n = 2, 1 cPR with PD at 8 m). SD was best response in 9 pts (9.6%). Conclusions: AL101 at the RP2D was generally well-tolerated and demonstrated sustained Notch inhibition as well as clinical activity across different tumor types. Future trials will evaluate AL101 in tumors with Notch activating mutations. Clinical trial information: NCT01292655.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.004
Threshold uncertainty score0.013

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0020.000
Meta-epidemiology (broad)0.0020.001
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0010.001
Open science0.0010.000
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0040.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.076
GPT teacher head0.523
Teacher spread0.447 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations21
Published2018
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical Oncology→Same topicLung Cancer Treatments and Mutations→French-language works237,207→